Bone Biologics Corp BBLG.OQ BBLG.O is expected to show no change in quarterly revenue when it reports results on November 12 (estimated) for the period ending September 30 2025
LSEG's mean analyst estimate for Bone Biologics Corp is for a loss of 53 cents per share.
The mean earnings estimate of analysts had risen by about 78.5% in the last three months.
Wall Street's median 12-month price target for Bone Biologics Corp is $22.50, about 89.6% above its last closing price of $2.35
This summary was machine generated August 15 at 20:07 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)